Drugs / Reinovax PCV24 formulation 3
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06678620 | Apr 2024 → Apr 2025 overdue | pneumococcal infection | Shanghai Reinovax Biologics Co.,LTD | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Reinovax PCV24 formulation 3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06678620 ↗ |
| Modality | Vaccine | “24-valent pneumococcal conjugate vaccine (PCV24)” NCT06678620 ↗ |
| Route | Intramuscular | “intramuscular injection at the deltoid muscle of the upper arm” NCT06678620 ↗ |